Luteal cells produce progesterone that supports pregnancy. Steroidogenesis requires coordination of the anabolic and catabolic pathways of lipid metabolism. In the present study, the corpus luteum (CL) in early pregnancy established from luteal phase and pregnant phase was analyzed. The first study determined progesterone changes in the bovine CL at day 19 (early maternal recognition period) and day 90 in mid-pregnancy and compared them to the CL from day 12 of the estrous cycle. CL alternation was tested using two-dimensional polyacrylamide gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI- TOF). Comparing CL from luteal phase to those from pregnant phase counterparts, significant changes in expression level were found in 23 proteins. Of these proteins 17 were not expressed in pregnant phase CL but expressed in luteal phase counterpart, whereas, the expression of the other 6 proteins was limited only in pregnant phase CL. Among these proteins, vimentin is considered to be involved in regulation of post-implantation development. In particular, vimentin may be used as marker for CL development during pregnancy because the expression level changed considerably in pregnant phase CL tissue compared with its luteal phase counterpart. Data from 2-DE suggest that protein expression was disorientated in mid pregnancy from luteal phase, but these changes was regulated with progression of pregnancy. These findings demonstrate CL development during mid-pregnancy from luteal phase and suggest that alternations of specific CL protein expression may be involved in maintenance of pregnancy.

Methyl methanesulfonate (MMS) was fed to Drosophila melanogaster in order to investigate its toxic capability at developmental and adult stages, and the hereditary effect of toxicity and the potency for induction of sex-linked lethal mutation during the spermatogenesis by the means of an attached-X method. In the control group, the egg to adult viability of D. melanogaster was 95.2%, while 3.5mM and 5.0mM treated groups were 90.0% and 84.1%, respectively. In the case of their progenies (F_1), the viability was 96.9% in the control group, while 3.5mM and 5.0mM treated groups were 54.5% and 1.6%, respectively. Therefore, these differences between two generations show significant physiological toxic effects in the next generation. In the parental generation, the developmental time was calculated 11.05 days in the control group, 12.43 days in 3.5%mM treated group, and 13.23 days in 5.0mM. In the case of F_1 it was estimated 10.35 days in the control group, and 11.43 days in 3.5mM treated group. Compared with the control groups in two generations, the developmental time generally delayed as the dose of MMS increased. As to the sex-ratio, there was no differences between the control and MMS treated groups. The toxic values of adult stage showed which increased the frequency of mortality with MMS concentrations. The mortality at 120hr in the control group was 1.67% and it in 0.5mM MMS treated group 3.33%. In 2.5mM MMS treated group, it was 33.3% at 72hr, and it 95% at 120hr. The increase of the morality was shown from 72hr in 4.0mM treated group which was 100% at 96hr. There was the concentration-dependent induction of sex-linked lethal mutation during the spermatogenesis by means of an attached-X method, MMS had more pronounced effect in sperm and spermaid stages in D. melanogaster.